May 12, 2017
Portland, Ore.—UbiVac, www.ubivac.com, a private, clinical-stage immuno-oncology company with a lead product that educates the immune system to recognize and destroy cancer, announced that its co-founder, Bernard A. Fox, PhD, will address the International Symposium on Immunotherapy held 12-13 May at the Royal Society, London, England.
During his remarks, Dr. Fox will present positive results from the recently completed randomized, multi-center, Phase II clinical trial of UbiVac’s DPV-001 as adjuvant therapy for non-small cell lung cancer. His presentation detailed the process of exploiting autophagy to induce broad anti-cancer immunity in mice and humans.
UbiVac’s DRibble immunotherapy (DPV-001) is a first in class technology that combines more than 100 cancer targets including at least 13 National Cancer Institute (NCI) prioritized cancer antigens. DRibble vaccines are a disruptive technology able to overcome tolerance and induce or boost broad anti-cancer immunity. Since a pre-existing anti-cancer immune response is required for response to checkpoint blockade, UbiVac believes that DRibble technology is the ideal companion for combination immunotherapy providing a needed component to boost effectiveness of the pipeline of co-stimulatory and checkpoint antibodies that are approved or currently under development.
Preparing his remarks, Dr. Fox commented: “I am privileged and humbled to have been selected to do this, and to think that I will be speaking in the same hall where Darwin spoke.” Dr. Fox’s remarks comprise the Royal Society’s Holbrook Kohrt memorial lecture. Holbrook Kohrt, MD, PhD, (1977-2016), was an assistant professor at the Stanford University School of Medicine renowned for his clinical trials research examining novel immunologic approaches and his translational research on novel therapies to enhance antitumor immunity.
Award Number R44CA121612 from the National Cancer Institute supports the research and clinical trial of DPV-001 in patients with NSCLC. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
UbiVac is a clinical stage Immuno-Ongology company engaged in development of immunotherapies to combat cancer. UbiVac’s DPV-001 recently completed a Phase II randomized multi-center adjuvant study for non-small cell lung cancer that documented efficacy for induction or boosting of broad anti-cancer immunity. Based on these data UbiVac is planning to open a phase Ib/II study of DPV-001 + anti-OX40 in patients with advanced cancer. UbiVac has ongoing preclinical and discovery programs using DRibble, nanoparticles and spread-defective Cytomegalovirus (sdCMV). Founded in Portland, Ore. in 2005 by Drs. Bernard A. Fox and Hong Ming Hu, UbiVac is a spinout of the Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute at Providence Portland Medical Center. In 2011 UbiVac, in cooperation with Oregon Health & Science University (OHSU), created UbiVac CMV to license sdCMV.